2 results
Approved WMOCompleted
Primary Safety Objective: To describe the safety profile of 20vPnC
Approved WMORecruiting
Primary objective:To evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e., previously treated…